IDEAYA Biosciences, Inc.
IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methyltā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$33.05
Price+5.10%
$1.60
1Y
Price
Market Cap
$2.903b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-858.5%
EBITDA Margin-765.7%
Net Profit Margin-835.1%
Free Cash Flow Margin-858.5%
EBITDA Margin-765.7%
Net Profit Margin-835.1%
Free Cash Flow MarginRevenue
$218.710m
+3024.4%
1y CAGR+966.8%
3y CAGR+745.6%
5y CAGREarnings
-$113.698m
+58.6%
1y CAGR-59.0%
3y CAGR-48.7%
5y CAGREPS
-$1.28
+61.0%
1y CAGR-16.1%
3y CAGR-12.3%
5y CAGRBook Value
$1.023b
$1.109b
Assets$86.390m
Liabilities$27.914m
DebtDebt to Assets
2.5%
-0.5x
Debt to EBITDAFree Cash Flow
-$73.466m
+70.8%
1y CAGR-24.3%
3y CAGR-32.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company